Compare Advanced Micro Devices (AMD) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advanced Micro Devices vs Merck & Co., Inc. — how do they compare? Advanced Micro Devices trades at $539.38 (market cap $909.70B), while Merck & Co., Inc. trades at $124.03 (market cap $305.12B). The key difference: Advanced Micro Devices is far larger — about 3× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays a 2.75% dividend while Advanced Micro Devices pays none. Which is the better fit depends on your goals.
| AMD | MRK | |
|---|---|---|
Market Cap | $909.70B | $305.12B |
Sector | Technology | Health |
52-Week High | $580.91 | $129.52 |
52-Week Low | $146.24 | $77.60 |
Enterprise Value | $901.22B | $348.54B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMD trades at $557.89, up 2.04% today and near its 52-week high, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth, with 2025 revenue reaching $34.64 billion and net income surging to $4.34 billion, though valuation ratios like P/E of 185.96 indicate premium pricing. Recent earnings beats and positive AI-driven news fuel investor optimism.
Outlook remains positive due to AI demand and earnings momentum, but high valuations and intense competition pose risks. Analyst consensus is strongly bullish with a $508.24 price target, though the stock trades above this, suggesting near-term caution amid long-term growth potential.
Merck (MRK) trades at $124.03, up 0.4% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with $65.01B revenue, 28.07% net margin, and consistent earnings beats. Recent acquisition of Terns Pharmaceuticals for $6.7B strengthens its oncology pipeline. Cash flow remains positive at $1.37B despite increased investing activity.
Merck presents a favorable investment case with 67.6% analyst buy ratings and $135.14 price target offering 9% upside. Key risks include patent expirations, regulatory pressures, and integration challenges from recent acquisitions. The stock's current valuation at 34.8 P/E appears reasonable given growth prospects and dividend yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
